Phase II trials were performed to combine HDAC inhibitors (panobinostat or vorinostat) and rituximab (an anti-CD20 antibody) in patients with DLBCL or indolent NHL (Chen et al., 2015; Assouline et al., 2016). Here, HDAC9 is linked to non-Hodgkin lymphoma.